The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Richard Ramanius - Redeye AB - Analyst
: Good afternoon. I have a few questions, starting with TRIFOUR. Could you specify what data points you will disclose in H1? And what new data in
H2 2025?
Question: Richard Ramanius - Redeye AB - Analyst
: Then I had some questions about second line lung cancer. Would you say that from your experience, IL1RAP is up regulated after first-line treatment
with checkpoint inhibitor?
Question: Richard Ramanius - Redeye AB - Analyst
: And another question on -- also on lung cancer. What is the unmet need for the second line after using checkpoint inhibitors in the first line?
Question: Richard Ramanius - Redeye AB - Analyst
: What can you say about the funding for the Phase II study of CAN10?
Question: Richard Ramanius - Redeye AB - Analyst
: Okay. Last question. Would it be correct to characterize the diagnosis test you're developing for nadunolimab, but you mentioned you could use
it for CAN10 as well as a companion diagnostic?
Question: Richard Ramanius - Redeye AB - Analyst
: Very well. That's all for me.
Question: Luisa Morgado - Van Lanschot Kempen - Analyst
: Hi, team. Thank you for taking my questions. Maybe the first one, in terms of the pancreatic cancer program. You mentioned that this might pursue
under the former of a Phase II or Phase III. Could you elaborate a bit more on what this spend on? And when will we see the first results from this
trial?
Question: Luisa Morgado - Van Lanschot Kempen - Analyst
: Okay. Makes sense. Thank you. And in terms of -- so if you -- assuming that the rights issue is goes through, what does the new cash runway cover
in terms of all the programs that you have now?
Question: Luisa Morgado - Van Lanschot Kempen - Analyst
: No, no, no. It does answer. And maybe a follow-up question for you, Patrik. In terms of the expenses for the remainder of the year and also next
year, what can we expect here?
Question: Luisa Morgado - Van Lanschot Kempen - Analyst
: Okay. That's quite helpful. Thank you. That's all from my side.
| 
